Moreover, the overexpression of RTN4A was found in the whole spectrum of the disease (at the onset of MS, in a long-lasting and advanced stage of disease), which may indicate the possibility of using it as a potential biochemical marker of the disease [25]. This evidence concerns the gene RTN4 and myeloid sarcoma.